Chescapmanager LLC reduced its position in shares of Allergan PLC. (NYSE:AGN) by 3.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 59,000 shares of the company’s stock after selling 2,000 shares during the period. Allergan PLC. comprises about 1.9% of Chescapmanager LLC’s holdings, making the stock its 10th largest position. Chescapmanager LLC’s holdings in Allergan PLC. were worth $14,096,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Trust Co. of Vermont boosted its stake in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after buying an additional 1,109 shares during the last quarter. Israel Discount Bank of New York acquired a new stake in shares of Allergan PLC. during the first quarter worth approximately $988,000. BKD Wealth Advisors LLC acquired a new stake in shares of Allergan PLC. during the first quarter worth approximately $219,000. Fulton Bank N.A. boosted its stake in shares of Allergan PLC. by 12.8% in the first quarter. Fulton Bank N.A. now owns 5,602 shares of the company’s stock worth $1,338,000 after buying an additional 637 shares during the last quarter. Finally, Rehmann Capital Advisory Group boosted its stake in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock worth $425,000 after buying an additional 237 shares during the last quarter. Hedge funds and other institutional investors own 84.77% of the company’s stock.
Allergan PLC. (NYSE:AGN) opened at 239.74 on Wednesday. The company’s 50 day moving average is $246.48 and its 200 day moving average is $237.35. The company has a market cap of $80.52 billion, a price-to-earnings ratio of 7.47 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the business posted $3.35 earnings per share. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts forecast that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.
A number of analysts recently commented on AGN shares. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Mizuho decreased their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a report on Friday, June 9th. Cantor Fitzgerald started coverage on shares of Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 target price on the stock. Finally, Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a report on Tuesday, July 11th. Eight research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Allergan PLC. currently has a consensus rating of “Buy” and a consensus price target of $274.24.
In related news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.
